The behavioral response of mice to infection is often demonstrated by a reduction in physical activity. Although it is known that single-stranded (ss) RNA, one of the genomes found in viruses, activates to produce type I interferon (IFNs) and pro-inflammatory cytokine via toll-like receptor (TLR) 7, the effect of TLR7 activation on spontaneous wheel-running activity is little known. To determine whether physical activity is regulated by TLR7 activation or not, we measured R-848 (which is a TLR7 agonist) -induced changes in spontaneous wheelrunning activity in mice. Male C3H/HeN mice were IV injected with R-848 (0, 1 and 5 mg/kg), and their wheel-running activity was measured. Also, to clarify the effects of R-848-induced IFN-α, tumor necrosis factor (TNF)-α and prostaglandin (PG) E2 on wheel-running behavior, the R-848-injected wheel-running mice were treated with an inhibitor such as a neutralizing antibody specific to IFN-α, pentoxifylline (PTX) and indomethacin (IDM), respectively. It was observed that dose-dependent R-848 treatment reduced wheel-running activity, and the treatment induced an increase in plasma IFN-α, TNF-α, and PGE2 concentrations. However, the wheel-running activity was not attenuated by the anti-IFN-α antibody, PTX and IDM treatments. Our results suggest that the transient reduction in physical activity after R-848 injection is dose dependent, and that these phenomena might occur independently of the behavior caused by R-848-induced IFN-α, TNF-α and PGE2 via TLR7.
Introduction
One characteristic of sickness behavior is lethargy. This sickness behavior is a motivational state that is common to most pathogen-induced infections. In animal experiment models, sickness behavior after infection is often measured by spontaneous wheel-running activity [1] [2] [3] [4] . The innate immune system relies on pattern recognition receptors (PRRs) for the detection of pathogens. The tolllike receptors (TLRs) are a discovered family of PRRs 5) . Of the 13 mammalian TLR members identified to date, TLR7/8 have been characterized as the principal sensors of RNA viruses (e.g. influenza virus, herpes simplex virus and HIV) that are activated by single-stranded (ss) RNA rich in G/U residues in endosomes of dendritic cells 6, 7) . Although we and other researchers have shown that PRRs induced activation of several TLRs (such as TLR2, TLR3, TLR4, TLR5 and TLR6) causing a reduction in locomotor activities such as spontaneous wheel-running activity in mice 2, 3, 8, 9) , activation of TLR7 (It has been believed that mouse TLR8 is biologically inactive 10) .) has been given relatively little attention as a direct modifier of animal behavior 4) . In addition, the two previous research experiments were not consistent in their results. In other words, it could not be determined whether or not TLR7 agonists induced 11, 12) the reduction of physical activity. R-848 (resiquimod) is an imidazoquinoline that activates immune cells via TLR7/8. It is the most potent inducer of type I interferon (IFN) 13, 14) , pro-inflammatory cytokine tumor necrosis factor (TNF) -α 11, 12, 14) , and prostaglandin (PG) E2 11) . However, it is not entirely clear whether or not R-848 induces voluntary physical activity. Although IFN-α has been used to treat human patients with viral infections or cancer, at the onset of treatment, patients experience reduced physical activity with fatigue, pain, anorexia and fever 4) . In addition, because Raison et al. (2009) 15) suggested that increased IFN-α might contribute to behavioral changes, we especially focused on the effect of R-848-induced IFN-α on sickness behavior.
The present study examined the changes in spontaneous wheel-running activity in mice after R-848 injection. Of importance is the fact that we used R-848-challenged mice to determine whether or not R-848-induced IFN-α, TNF-α and/or PGE2 production were responsible for *Correspondence: yanohiro@mw.kawasaki-m.ac.jp reducing the wheel-running activity in the mice. We hypothesized that the injection of R-848 induces a reduction in wheel-running activity via TLR7.
Materials and Methods
Animals. Nine or ten-week-old male C3H/HeN mice (CLEA Japan, Tokyo, Japan), weighing 20-24 grams (g), were housed in a controlled environment at 22 ± 1°C on a 12:12 h light-dark cycle from 8:00 to 20:00, and maintained on food and water available ad libitum. The experimental procedures followed Guiding Principles for the Care and Use of Animals in the KUMW and approved by the Kawasaki University Medical Welfare Institutional Animal Care and Use Committee (IACUC) (08-009).
Reagents. The reagents used in the experiments were R-848 (Alexis Biomedicals, San Diego, CA), and rabbit polyclonal anti-mouse IFN-α antibody (Abcam, Cambridge, MA). These reagents were dissolved in pyrogenfree phosphate buffer saline (PBS) and were freshly prepared on the day of each experiment. Pentoxifylline (PTX) and indomethacin (IDM) were obtained from Sigma (St. Louis, MO) and Nacalai Tesque (Kyoto, Japan), respectively. These reagents were dissolved in dimethyl sulfoxide (DMSO) and then diluted with pyrogen-free PBS.
Testing the effect of the R-848 injection on wheel-running activity in mice (test #1). Mice were divided into three groups and injected intravenously (IV) with R-848, 0 mg/kg (Vehicle group, n = 10), 1 mg/kg [low-dose (LD) group, n = 10] or 5 mg/kg [high-dose (HD) group, n = 10] in 100 μl PBS. Each mouse was lightly anesthetized with inhalant Isoflurane prior to IV injection via the orbital vein. The experimental procedures were conducted between 12:30 and 13:00 hours to reduce the variability associated with diurnal rhythms. Spontaneous physical activity was evaluated by wheel-running activity, which was measured by a cage-adjacent wheel (10 x 23 x 10 cm cage with wide 5.5 cm x φ 22 cm wheel, Natsume Seisakusho, Tokyo, Japan) for 24 hours before and after the R-848 injection. Wheel running counts of 5 mice by random sampling in each group were recorded every hour for 24 hours after the R-848 injection using a recorder (Counting & Accumulating Printer, Natsume Seisakusho). Body weight and food intake were measured before and at 24 hours after the R-848 injection.
Testing the effect of the R-848 injection on plasma IFN-α, TNF-α and PGE2 concentrations in mice (test #2). Mice were IV injected with 5 mg/kg R-848 in 100 μl PBS (R-848 group, n = 14) or with PBS alone (Vehicle group, n = 5) under Isoflurane anesthesia between 12:30 and 13:00 according to the experimental condition described above. Blood samples were taken from the orbital vein at the time of or before the R-848 injection, and 1, 3, 6 and 24 hours after the R-848 injection under Isoflurane anesthesia. After centrifugation, plasma was collected and stored at -40˚C until assayed to measure the plasma IFN-α and TNF-α concentrations.
To measure the changes in plasma PGE2 concentration in response to R-848, other mice were IV injected with 5 mg/kg R-848 (n = 12) or with PBS alone (Vehicle group, n = 5) under Isoflurane anesthesia. Blood samples were taken from the abdominal vein at the time of one hour after the R-848 or PBS injections under Isoflurane anesthesia. Collected plasma was stored at -40˚C until assayed to measure the plasma PGE2 concentration.
Testing the effect of anti-IFN-α antibody, PTX and IDM treatments on wheel-running activity in R-848-injected mice (test #3). Mice were divided into eight groups. Mice were IV injected with PBS at 0, 4 and 8 hours as Vehicle (V) alone (V + V group, n = 10), with R-848 (5 mg/kg) at 0 hours and with PBS at 0, 4 and 8 hours (R848 + V group, n = 11), with PBS at 0 hours and with anti-IFN-α antibody (1,000 neutralizing U) at 0, 4 and 8 hours for a total of 1.5 x 10 5 U/kg (V + IFNAB group, n = 10), and with R-848 at 0 hours and anti-IFN-α antibody at 0, 4 and 8 hours (R848 + IFNAB group, n = 10)
3) . Other mice were IV injected with PBS at 0 hours and with pentoxifylline [PTX, 20 mg/kg, IP (intraperitoneal injection)] 16) 30 mins (-0.5 hours) prior to it (V + PTX group, n = 9), with R-848 at 0 hours and with a PTX at -0.5 hours (R848 + PTX group, n = 10), with PBS (IV) at 0 hours and with an indomethacin (IDM, 10 mg/kg, IP) 9) at -0.5 hours (V + IDM group, n = 9), and R-848 at 0 hours and with an indomethacin (10 mg/kg, IP) at -0.5 hours (R848 + IDM group, n = 11). All of these injections were into the orbital vein (IV) or IP after each mouse was lightly anesthetized with inhalant Isoflurane, and each injection volume was 100 μl per mouse (IV) and 200 μl per mouse (IP), respectively. The experimental procedure was also started between 12:30 and 13:00 hours to reduce the variability associated with diurnal rhythms. Spontaneous physical activity was evaluated by wheel-running activity, which was measured by a cage-adjacent wheel as well as by the testing above. Body weight and food intake were measured before R-848 and at 24 hours after the R-848 injection.
Assay of IFN-α TNF-α and PGE2 concentrations. Plasma IFN-α and TNF-α concentrations were measured using the mouse IFN-α ELISA kit (PBL Biomedical Lab, Piscataway, NJ) and the mouse TNF-α ELISA kit (R&D Systems, Minneapolis, MN), respectively. PGE2 concentration in plasma was measured using the PGE2 EIA System (GE Healthcare, Buckinghamshire, UK). Those detection limits were >12.5 pg/ml, >5.1 pg/ml, and >50 pg/ml, respectively. All sample determinations were measured in duplicate and mean values were calculated.
Statistical analysis. All data are expressed as the means ± SEM. Statistical calculations were carried out with SPSS 15.0J (Japan) for Windows. Data for body weight and food intake in test #1 were analyzed with the one-way analysis of variance (ANOVA). Wheel-running activity in test #1, and TNF-α and IFN-α concentrations in plasma in test #2 were analyzed with the two-way repeatedmeasures ANOVA. Wheel-running activity, body weight and food intake in test #3 were analyzed with the twoway ANOVA. The Post-hoc test was performed by using Tukey's or Bonferroni's tests. Data for plasma PGE2 concentration in test #2 was analyzed with the unpaired ttest. Data were considered significantly different when p < 0.05.
Results
First, we evaluated the wheel-running activity of mice after high-(HD) and low-(LD) dose R-848 administration. The activity varied as a function of R-848 treatment; F(2,12) = 5.51, p < 0.05, time; F(23,276) = 7.94, p < 0.01, and R-848 treatment x time interaction, F(46,276) = 1.63, p < 0.05. The mice given HD R-848 showed significantly depressed wheel-running activity at 20:00 (p < 0.05) and 23:00 (p < 0.05), respectively, when compared to the Vehicle group (Fig. 1A) . The total wheel-running activity for 24 hours before and after R-848 administration in the mice varied as a function of pre-and post-R-848 treatment; F(1,27) = 74.73, p < 0.01, the dose of R-848 treatment; F(2,27) = 11.15, p < 0.01, and the interactions; F(2,27) = 8.68, p < 0.01. The total wheel-running activ- 
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ity was not decreased in the Vehicle mice. The activity in both LD and HD groups was significantly depressed after each dose of R-848 treatment (p < 0.01, respectively, Fig.  1B ). Thus, the activity was decreased in the R-848 dosedependent mice. These data demonstrate that ssRNA induces a reduction in wheel-running activity. Table 1 shows the change in body weight [F(2,27) = 9.55, p < 0.01] and the food intake [F(2,27) = 9.54, p < 0.01] in each group. Although the change in body weight between the Vehicle and LD R-848 groups were not different, the HD R-848 treatments induced a significant decrease in body weight compared to the Vehicle (p < 0.01) and LD R-848 groups (p < 0.01). The food intake in the Vehicle mice was significantly higher than that in both LD R-848 and HD R-848 treated groups (p < 0.05 and p < 0.01, respectively).
Next, we examined plasma IFN-α concentrations in mice before and after R-848 injections ( Fig. 2A) . As for results, the ANOVA indicated time; F(4,68) = 28.35, p < 0.01, R-848 (5 mg/kg) treatment; F(1,17) = 37.59, p < 0.01, and time x R-848 treatment interaction; F(4,68) = 24.84, p < 0.01. In the one hour after the R-848 injection, the plasma IFN-α concentration significantly increased 2881 ± 268 pg/ml compared to 243 ± 76 pg/ml for the Vehicle group (p < 0.01). This significant increase in IFN-α was observed from three to six hours after the R-848 injection (p < 0.01 and p < 0.05, respectively).
Furthermore, to clarify the effect of R-848 on plasma Table 1 . Changes in D body weight and food intake in mice after R-848 injection LD; R-848 (1mg/kg) treated group, and HD; R-848 (5mg/kg) treated group. * p<0.05 and ** p<0.01 vs. Vehicle, and tt p<0.01 vs. LD.
Treatment
Body weight Food intake (n) ( g/day) (%) ( g/day)
Vehicle ( TNF-α induction in vivo, we examined plasma TNF-α concentrations in mice before and after R-848 injections. As for results, the ANOVA indicated time; F(4,68) = 16.80, p < 0.01, R-848 (5 mg/kg) treatment; F(1,17) = 15.55, p < 0.01, and time x R-848 treatment interaction; F(4,68) = 16.80, p < 0.01. In one hour after the R-848 injection, the plasma TNF-α concentration significantly increased 2046 ± 283 pg/ml as compared to non-detection for the Vehicle group (p < 0.01). This significant increase in TNF-α was observed at three hours after the R-848 injection (p < 0.01, Fig. 2B ). Plasma PGE2 concentrations in R-848-treated mice were also significantly higher than that in the Vehicle group (p < 0.05, Fig. 2C) .
Finally, to clarify whether or not INF-α causes R-848-induced sickness behavior, the wheel-running activity in anti-IFN-α antibody-treated mice after R-848 injection was observed (Fig. 3) . The wheel-running activity varied as a function of pre-and post-treatment; F(1,72) = 92.62, p < 0.01, several treatments; F(3,72) = 4.64, p < 0.01, and these interactions; F(3,72) = 2.91, p < 0.05. In addition, the percentages of wheel-running activity varied as a function of pre-and post-treatment; F(1,72) = 82.54, p < 0.01, several treatments; F(3,72) = 2.10, N.S.(not significant), and these interactions; F(3,72) = 2.20, N.S. Although a slight difference between the value of wheelrunning activities in the V + V and the V + IDM groups was significantly shown (p < 0.05), the percentage of the activities in those groups did not show any difference (Data not shown). A significant decrease in wheel-running activity was observed among the R848 + V, the R848 + IFNAB, the R848 + PTX and the R848 + IDM mice (p < 0.01, respectively). Namely, the activities in those groups also showed that R-848-induced reductions of wheelrunning activity were not inhibited by IFNAB, PTX and IDM.
There were also changes in body weight and food intake with several treatments [body weight: pre-and posttreatment; F(1,72) = 53.49, p < 0.01, several treatments; F(3,72) = 3.18, p < 0.05, and these interactions; F(3,72) = 0.209, N.S.], and [food intake: pre-and post-treatment; F(1,72) = 53.37, p < 0.01, several treatments; F(3,72) = 2.23, N.S., and these interactions; F(3,72) = 5.01, p < 0.01]. The changes in body weight were slightly, but significantly different between the V + V group and all of the R-848-treated groups (R848 + V; ~95%, p < 0.01, R848 + IFNAB; ~97%, p < 0.01, R848 + PTX; ~96%, p < 0.01 and R848 + IDM; ~98%, p < 0.01). Furthermore, the food intake in these R-848-treated groups (R848 + V, R848 + IFNAB and R848 + PTX) was significantly lower than that of each untreated R-848 group (vs. V + V, V + IFNAB and V + PTX, p < 0.01 or p < 0.05, respectively). Also, the difference between food intake in V + IFNAB and V + IDM (p < 0.01, Table 2 ) was observed.
Discussion
A remarkable finding of our study was that R-848, which is a TLR7 agonist, induced a dose dependent reduction in wheel-running activity in mice. Although R-848 increased plasma IFN-α, TNF-α, and PGE2 concentrations, each inhibitor did not attenuate an R-848-induced reduction of wheel-running activity. increased IFN-α might contribute to behavioral changes, whereas McCusker and Kelley (2013) 4) suggested that IFNs (IFN-α, IFN-β and IFN-γ) were not directly responsible or required for sickness behavior. Although IFN-α acts as a pyrogenic factor by altering the activity of thermosensitive neurons in the hypothalamus, thus causing fever 20) , IFN-α alone might not have an effect on physical behavior because there is no pre-existing pro-inflammatory response to amplify. The results suggest that selective inhibition of R-848-induced IFN-α does not contribute to a recovery from sickness behavior after R-848 injection. Thus, there is no evidence that IFN-α via TLR7 activation could play a role in wheel-running activity in mice.
Hubschle et al. (2006) 8) reported that stimulation of TLR2 and TLR6, which do not have an MyD88 independent pathway, also induced reduction of locomotion movement in rats. In addition, when LPS induces a reduction in physical activity, type I IFN is not induced 21) . Therefore, IFN-α might not be related to or regulate an R-848-induced reduction in wheel-running activity directly. Indeed, McCusker and Kelly (2013) 4) suggest that the IFNs signal through the JAK/STAT pathway plays only a little part in altering behavior compared with TNF-α activate cascades leading to nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MARK) activation.
Secondly, R-848 is believed to be mediated by targeting of TLR7, and TLR7 signaling activates NF-κB and/ or IRF7 5) . Although pro-inflammatory cytokines (such as TNF-α), which are led by NF-κB activation, are known to play a role in the behavioral partiality effect of infection 4) , the reductions in spontaneous physical activity after infection could not be completely inhibited by anti-IL-1β, anti-IL-6 and anti-TNF-α antibody treatments 22) . Therefore, NF-κB-induced pro-inflammatory cytokines may not be the main factor inducing a reduction in spontaneous activity after infection. Our results that state that Hayashi et al. (2008) 11) reported that the locomotor activity was decreased in the TLR7 agonist injected mice. Our observations might be supported by the report. In addition, the TLR4 agonist lipopolysaccharide (LPS) 9) , TLR2/6 agonists MALP-2 and FSL-1 8) , and TLR5 agonist flagellin 2) reduced voluntary physical activity in animal experiments. Moreover, we and others, using wheel-running activity, reported that dsRNA poly I:C was also associated with a reduction in spontaneous physical activity 3) . Thus, pathogen recognition via TLR7 induces a reduction in physical behavior as well as via other TLRs.
At first, our hypothesis was that an R-848-induced reduction of wheel-running activity might be regulated by IFN-α via TLR7 signaling, because interferon regulatory factor (IRF) 3 leads to the expression of type I IFNs, which mean IFN-α and -β 5) . A previous study reported that IFN-α expression in the brain increased when the TLR3 agonist induced prolonged fatigue (for seven days) in mice 17) . Furthermore, another study, using a forced treadmill exercise, reported that the TLR3 agonist was associated with a reduction in run time to fatigue, and this phenomenon slightly attenuated the anti-IFN-α/β antibody 18) . Indeed, our study showed that the wheel-running activity in the R-848 injected mice was much lower than that of the control (Vehicle-treated) mice. The reduction in wheel-running activity depended on the dose of R-848 administered. We hypothesized that R-848-induced IFN-α would play a role in the reduction of wheel-running activity seen after systemic R-848 administration because ssRNA is best known as a potent inducer of IFN-α 19) . In addition, it was reported that IFN-β, which is another type I IFN, did not directly affect pathogen-induced reduction wheel-running activity in mice 3) . However, surprisingly, the injection of a neutralizing antibody to IFN-α did not attenuate a reduction in wheel-running activity in the R-848 treated mice. Raison et al. (2009) 15) suggested that tion of high doses of only IDM causes side effects such as decreased physical activity. Even so, this study showed a reduction of physical activity was observed in IDM treatments without R-848. We thought that there was some limitation in this research.
In summary, we found R-848 to be a TLR7 agonist that induces doses dependent on a reduction in wheelrunning behavior. In addition, although the concentrations of plasma IFN-α, TNF-α and PGE2 were increased by R-848 injection, the reduction in wheel-running behavior was not attenuated by each inhibitor treatment. In conclusion, the current study suggests that the transient reduction in physical activity after R-848 injection induces dose dependence, and that these phenomena might occur independently of the behavior caused by R-848-induced IFN-α, TNF-α and PGE2 via TLR7. Therefore, ssRNAinduced sickness behavior might not be directly regulated by IFN-α, TNF-α and PGE2. These findings clearly demonstrate the effects of ssRNA on physical behavior and IFN-α, TNF-α and PGE2 responses, and should be useful in studying aspects of the effects of systemic viral infection in both normal and pathological situations.
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The authors declare that there is no conflict of interests regarding the publication of this article. a TNF-α inhibitor PTX did not attenuate R-848-reduced wheel running activity of mice, also supported the previous study. Accordingly, at least R-848-reduced TNF-α did not relate to or regulate the reduction of wheel-running activity after R-848 injection.
Finally, we investigated another hypothesis, that R-848/ TLR7-induced PGE2 might regulate sickness behavior. We already showed that LPS-induced sickness behavior inhibited TLR4 point-mutated mice completely, and the sickness behavior of wild-type mice was also attenuated by PGE2 inhibitor 9) . In addition, R-848 induced increasing PGE2 concentrations in plasma. However, IDM treatment, which diminished PGE2 production via inhibition of cyclooxygenase (COX) 2 activation, did not recover the wheel running activity in R-848 induced mice with sickness behaviors. It was reported that a TLR7 agonist, 1V136, induced reduction of food intake and loss of body weight in mice 11) . Moreover, this agonist-induced anorexia was neither observed in Tnf-α -/-and Cox2 -/-mice, nor in Tlr7 -/-mice. Accordingly, in our study, TLR7 activation by R-848 might induce anorexia via TNF-α and/ or PGE2 production. In addition, Damm, et al. (2012) 12) showed that there was no change in physical activity despite decreased food intake after injection of another TLR7 agonist R-837. This previous study also observed the increase in plasma TNF-α concentration and Cox2 expression in the brain. Indeed, we showed that PTX and IMD treatments before R-848 stimulation attenuated the reduction of food intake compared to Vehicle or IFN antibody injections (R848 + V / V + V; 51% and R848 + IFNAB / V + IFNAB; 49% vs. R848 + PTX / V + PTX; 73% and R848 + IDM / V + IDM; 84%). Especially, the food intake in IDM-treated mice did not show a significant difference between the V + IDM and R848 + IDM groups. However, IDM treatment did not attenuate the diminished wheel running activity after the R-848 injection. These data indicate that R848-initiated anorexia and low physical activity might have played either a predominant role in producing sickness behavior responses or a different mechanism.
In this study, a limitation was that brain functions have not been observed. Accordingly, Cunningham et al. (2007) 23) reported that plasma concentrations of IFN and its mRNA expression in the brain were markedly elevated when poly I:C-induced sickness behavior in mice was observed. Accordingly, we still could not say with confidence that IFN-α is not involved in R-848-induced reduction of voluntary physical activity. Further studies will be needed to determine whether the R-848-induced reduction of physical activity is influenced by the blockage of IFN-α in the brain. In addition, not only R-848 treatment, but a PGE2 inhibitor IDM treatment-induced reduction in physical activity. It is known that the effect of IDM acts to suppress the reduction of LPS-induced physical activity in a concentration-dependent manner, but the effect saturates at high doses of IDM 9) . Therefore, administra-
